bevacizumab, ranibizumab, aflibercept and ziv ... - Semantic Scholar

2 downloads 111 Views 2MB Size Report
ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Deepika Malik,1 Mohamed Tarek,1,2 Javier Caceres del Carpio ...
Original article

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture Deepika Malik,1 Mohamed Tarek,1,2 Javier Caceres del Carpio,1 Claudio Ramirez,1 David Boyer,3 M Cristina Kenney,1 Baruch D Kuppermann1 1

Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, California, USA 2 Department of Ophthalmology, El-Minya University, El-Minya, Egypt 3 Retina-vitreous Associates Medical Group, Los Angeles, California, USA Correspondence to Dr Baruch D Kuppermann, Department of Ophthalmology, Gavin Herbert Eye Institute, UC, Irvine, 850 Health Sciences Road, Irvine, CA 92697, USA; [email protected] Received 25 March 2014 Accepted 30 March 2014

ABSTRACT Purpose To compare the safety profiles of antivascular endothelial growth factor (VEGF) drugs ranibizumab, bevacizumab, aflibercept and ziv-aflibercept on retinal pigment epithelium cells in culture. Methods Human retinal pigment epithelium cells (ARPE-19) were exposed for 24 h to four anti-VEGF drugs at 1/2×, 1×, 2× and 10× clinical concentrations. Cell viability and mitochondrial membrane potential assay were performed to evaluate early apoptotic changes and rate of overall cell death. Results Cell viability decreased at 10× concentrations in bevacizumab (82.38%, p=0.0001), aflibercept (82.68%, p=0.0002) and ziv-aflibercept (77.25%, p